The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Roche; Takeda; Takeda
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Inivata; Stilla Technologies
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Takeda
Prevalence of incidental pathogenic germline variants detected in cfDNA in patients with oncogene-driven non-small cell lung cancer.
 
Laura Mezquita
No Relationships to Disclose
 
Leslie A. Bucheit
Employment - Guardant Health; Myriad Genetics
Stock and Other Ownership Interests - Guardant Health
 
Juan Carlos Laguna
No Relationships to Disclose
 
Belen Pastor
No Relationships to Disclose
 
Cristina Teixido
No Relationships to Disclose
 
Teresa Gorria
No Relationships to Disclose
 
Victor Albarran-Artahona
No Relationships to Disclose
 
Marta Garcia de Herreros
No Relationships to Disclose
 
Roxana Reyes
No Relationships to Disclose
 
Noemi Reguart
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Boehringer Ingelheim; Janssen; Lilly; MSD Oncology; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Merck Serono; MSD; Novartis; Roche; Roche Molecular Diagnostics; Sanofi; Takeda
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - MSD; Roche
 
Nuria Vinolas
Speakers' Bureau - Bristol-Myers Squibb/Medarex; Pfizer; Roche
 
Ainara Arcocha
No Relationships to Disclose
 
Joan Anton Puig-Butillé
No Relationships to Disclose
 
Leylah Drusbosky
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Travel, Accommodations, Expenses - Guardant Health
 
Iris Faull
Employment - Guardant Health; Nanostring Technologies
Stock and Other Ownership Interests - Guardant Health; Nanostring Technologies
Honoraria - Guardant Health; NanoString Technologies
Travel, Accommodations, Expenses - Guardant Health; NanoString Technologies
 
Elena Castro
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Janssen-Cilag; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; MSD Oncology; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Janssen (Inst); SYNLAB (Inst)
Expert Testimony - Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Janssen; Roche
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Lilly; Takeda Science Foundation
Research Funding - Bristol-Myers Squibb (Inst)
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); cergentis (Inst); Chugai Pharma (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)